SAN FRANCISCO, Jan 12 (Reuters) - Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Novo Nordisk was the first company to introduce GLP-1 weight loss drugs. Eli Lilly's GLP-1 drugs have since taken the lead in the emerging weight loss space. But Novo Nordisk now has a new pill ...

Eli Lilly (LLY +0.52%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in market value. The company briefly touched that level in November but has since ...

Novo Nordisk A/S is rated a buy, driven by FDA approval of its oral Wegovy, strong fundamentals, and attractive valuation versus Eli Lilly. Recent clinical data and first-mover advantage position ...

Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over ...

Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market. There are plenty of reasons to like the stock beyond this ...